"People actually talk these days about a potential return to the "pre-antibiotic era" where we no longer have effective tools to treat serious infectious disease. Clearly, we must encourage more judicious use of these important drugs through improved infection control, rational prescribing and better patient compliance. But even if we improve these practices, resistant bacteria will continue to develop. No matter what, we need new and better drugs…and we need them now. Yet the R & D pipeline is distressingly low..."
--Margaret A. Hamburg, M.D.
Commissioner, U.S. Food and Drugs Administration (FDA)
National Press Club Luncheon, October 6, 2010.
Only subscribers can access this article, which is part of the PRO research library covering 3,581 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: